142 related articles for article (PubMed ID: 10051059)
1. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.
Olesen OV; Linnet K
Ther Drug Monit; 1999 Feb; 21(1):87-90. PubMed ID: 10051059
[TBL] [Abstract][Full Text] [Related]
2. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication.
Linnet K; Olesen OV
Ther Drug Monit; 2002 Aug; 24(4):512-7. PubMed ID: 12142636
[TBL] [Abstract][Full Text] [Related]
3. Quetiapine serum concentrations in psychiatric patients: the influence of comedication.
Hasselstrøm J; Linnet K
Ther Drug Monit; 2004 Oct; 26(5):486-91. PubMed ID: 15385830
[TBL] [Abstract][Full Text] [Related]
4. [Monitoring of serum olanzapine during antipsychotic treatment].
Linnet K; Olesen OV
Ugeskr Laeger; 2000 Sep; 162(36):4802-5. PubMed ID: 10994377
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting.
Skogh E; Reis M; Dahl ML; Lundmark J; Bengtsson F
Ther Drug Monit; 2002 Aug; 24(4):518-26. PubMed ID: 12142637
[TBL] [Abstract][Full Text] [Related]
6. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication.
Theisen FM; Haberhausen M; Schulz E; Fleischhaker C; Clement HW; Heinzel-Gutenbrunner M; Remschmidt H
Ther Drug Monit; 2006 Dec; 28(6):750-9. PubMed ID: 17164690
[TBL] [Abstract][Full Text] [Related]
8. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers.
Penzak SR; Hon YY; Lawhorn WD; Shirley KL; Spratlin V; Jann MW
J Clin Psychopharmacol; 2002 Aug; 22(4):366-70. PubMed ID: 12172335
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication.
Gex-Fabry M; Balant-Gorgia AE; Balant LP
Ther Drug Monit; 2003 Feb; 25(1):46-53. PubMed ID: 12548144
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.
Lucas RA; Gilfillan DJ; Bergstrom RF
Eur J Clin Pharmacol; 1998 Oct; 54(8):639-43. PubMed ID: 9860152
[TBL] [Abstract][Full Text] [Related]
11. [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].
Rao ML; Hiemke C; Grasmäder K; Baumann P;
Fortschr Neurol Psychiatr; 2001 Nov; 69(11):510-7. PubMed ID: 11704898
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes.
Hägg S; Spigset O; Lakso HA; Dahlqvist R
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):493-7. PubMed ID: 11699614
[TBL] [Abstract][Full Text] [Related]
13. Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid.
Mao M; Skogh E; Scordo MG; Dahl ML
J Clin Psychopharmacol; 2012 Apr; 32(2):287-9. PubMed ID: 22388157
[No Abstract] [Full Text] [Related]
14. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
Meisenzahl EM; Dresel S; Frodl T; Schmitt GJ; Preuss UW; Rossmüller B; Tatsch K; Mager T; Hahn K; Möller HJ
J Psychopharmacol; 2000; 14(4):364-70. PubMed ID: 11198054
[TBL] [Abstract][Full Text] [Related]
15. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration.
Markowitz JS; DeVane CL
J Clin Psychopharmacol; 1999 Jun; 19(3):289-91. PubMed ID: 10350045
[No Abstract] [Full Text] [Related]
16. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine.
Licht RW; Olesen OV; Friis P; Laustsen T
J Clin Psychopharmacol; 2000 Feb; 20(1):110-2. PubMed ID: 10653223
[No Abstract] [Full Text] [Related]
17. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service.
Castberg I; Spigset O
Pharmacopsychiatry; 2007 May; 40(3):107-10. PubMed ID: 17541885
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men.
Macias WL; Bergstrom RF; Cerimele BJ; Kassahun K; Tatum DE; Callaghan JT
Pharmacotherapy; 1998; 18(6):1237-48. PubMed ID: 9855322
[TBL] [Abstract][Full Text] [Related]
19. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection.
Aravagiri M; Ames D; Wirshing WC; Marder SR
Ther Drug Monit; 1997 Jun; 19(3):307-13. PubMed ID: 9200772
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine excretion in human breast milk: estimation of infant exposure.
Croke S; Buist A; Hackett LP; Ilett KF; Norman TR; Burrows GD
Int J Neuropsychopharmacol; 2002 Sep; 5(3):243-7. PubMed ID: 12366877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
